Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

Inclusion Criteria: * Age 18 to 70 years. Because no dosing or adverse event data are currently available on the use of the combination of FLAG-Ida with venetoclax and asciminib in patients \<18 years of age, children are excluded from this study. * Newly diagnosed or relapsed/refractory: * BCR::ABL1-rearranged CML in myeloid BP or Philadelphia chromosomepositive or BCR::ABL1-rearranged AML as defined by the WHO 2022 criteria23 * BCR::ABL1-rearranged CML in lymphoid BP. * ECOG performance status ≤ 2. * Adequate liver, cardiac, renal and pancreatic function as defined by the following criteria: * Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome, hemolysis, or the underlying leukemia approved by the Principal Investigator (PI) * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 3 x ULN, unless due to the underlying leukemia approved by the PI * Creatinine clearance ≥ 30 mL/min * Serum amylase or lipase ≤ 1.5 x ULN * Left ventricular ejection fraction ≥ 40%. * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. * Human immunodeficiency virus (HIV)-infected patients on effective anti-r…